LGD-3303 explained

LGD-3303 is a drug which acts as a selective androgen receptor modulator (SARM), with good oral bioavailability. It is a selective agonist for the androgen receptor, producing functional selectivity with effective dissociation of anabolic and androgenic effects, acting as a partial agonist for androgenic effects, but a full agonist for anabolic effects.^[1] It has been investigated as a possible treatment for osteoporosis, and was shown in animal studies to enhance the effectiveness of a bisphosphonate drug.^[2]

Notes and References

1. Vajda EG, López FJ, Rix P, Hill R, Chen Y, Lee KJ, O'Brien Z, Chang WY, Meglasson MD, Lee YH . 6 . Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an orally available nonsteroidal-selective androgen receptor modulator ]. The Journal of Pharmacology and Experimental Therapeutics . 328 . 2 . 663–70 . February 2009 . 19017848 . 10.1124/jpet.108.146811 . 22107491 .
2. Vajda EG, Hogue A, Griffiths KN, Chang WY, Burnett K, Chen Y, Marschke K, Mais DE, Pedram B, Shen Y, van Oeveren A, Zhi L, López FJ, Meglasson MD . 6 . Combination treatment with a selective androgen receptor modulator q(SARM) and a bisphosphonate has additive effects in osteopenic female rats . Journal of Bone and Mineral Research . 24 . 2 . 231–40 . February 2009 . 18847323 . 10.1359/jbmr.081007 . 21995180 . free .